Novel 2019 coronavirus: Genome structure, clinical trials, and outstanding questions
- PMID: 32306751
- PMCID: PMC7327953
- DOI: 10.1177/1535370220920540
Novel 2019 coronavirus: Genome structure, clinical trials, and outstanding questions
Abstract
Early availability of the sequence, the genetic material of SARS-CoV-2 (the virus that causes COVID-19), has prompted efforts towards identifying a safe and effective vaccine in the current public health emergency. To that end, understanding the pathophysiology of disease is crucial for scientists around the world. Since conventional vaccine development and manufacturing may take several years, it is important to think about alternative strategies that we could use to mitigate imminent catastrophe. We hope that this article will open up new avenues and provide insights that could potentially save hundreds of lives affected by COVID-19.
Keywords: 2019-nCoV; COVID-19; China; MERS-CoV; SARS-CoV; SARS-CoV-2; Wuhan; coronavirus.
Figures
References
-
- WHO | Pneumonia of unknown cause – China. WHO, www.who.int/csr/don/05-january-2020-pneumonia-of-unkown-cause-china/en/ (accessed 7 March 2020)
-
- Gorbalenya AE, Baker SC, Baric RS, de Groot RJ, Drosten C, Gulyaeva AA, Haagmans BL, Lauber C, Leontovich AM, Neuman BW, Penzar D, Perlman S, Poon LLM, Samborskiy DV, Sidorov IA, Sola I, Ziebuhr J. The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol 2020; 5:536–44 - PMC - PubMed
-
- Wuhan Municipal Health Committee, www.wuhan.gov.cn/front/web/showDetail/2019123108989 (accessed 7 March 2020)
-
- Key coronavirus question: how are children affected? – Harvard Gazette, https://news.harvard.edu/gazette/story/2020/02/key-coronavirus-question-... (accessed 8 March 2020)
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous
